President and CEO
Dr. Scott Liu, one of the global partners of Fosun International Limited, the Co-founder, President and CEO at Shanghai Henlius Biotech Inc., a global biopharmaceutical company focusing on the development, production and commercialization of high-quality and affordable biosimilar, biobetter and novel therapeutic monoclonal antibodies. Dr. Liu has more than 25 years of experience in biopharmaceutical R&D, manufacturing and quality management. Prior to setting up Henlius in 2010, he has previously had postdoctoral training in Biology at Stanford University and has served several executive positions at United Biomedical, the Founding Director of the Biologics QC Department at Bristol-Myers Squibb Technical Operations, and the Director of QAL (QC) at Amgen Inc. Fremont (now Boehringer Ingelheim Fremont Inc.). Dr. Liu was the recipient of the Bristol-Myers Squibb“Technical Operations Presidential Award”in 2004. Furthermore, Dr. Liu led the promotion of industry-wide adoption of single-use manufacturing technology to support the production of clinical and commercial monoclonal antibody therapeutics, and actively participated in the development of Technical Guidelines of Biosimilar Development and Evaluation to promote the innovation and globalization of the biopharmaceutical industry in China. He received his Ph.D. degree in Biology from the Purdue University.